This study found that the adoption of the PHI test for patients with negative DRE and PSA score 4–10 ng/ml in Hong Kong has the potential to deliver significant cost savings although there are implications with a proportion of all grade cancers missed. The gene discussed is KLK3; the disease is cancer.